Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
LYNPARZA™ (olaparib) meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer
LYNPARZA provided a statistically-significant improvement in progression-free survival compared to chemotherapy
First positive randomized trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer
AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.
US FDA approves SYMBICORT for the treatment of asthma in pediatric patients
AstraZeneca today announced that the US Food and Drug Administration (FDA) approved SYMBICORT®(budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years. SYMBICORT 80/4.5 and 160/4.5 are already approved in the US to treat asthma in patients 12 years and older.
AstraZeneca announces subgroup analysis from FALCON trial comparing FASLODEX® (fulvestrant) to ARIMIDEX® (anastrozole)
Subset of patients with non-visceral disease may show increased sensitivity to FASLODEX in 1st line therapy of advanced breast cancer
AstraZeneca today announced results from a pre-specified subgroup analysis of the positive Phase III FALCON trial suggesting that treatment effects in terms of progression-free survival (PFS) were largely consistent across the subgroups analyzed with some possible exceptions, including patients with non-visceral disease.
TAGRISSO® (osimertinib) demonstrates superiority over chemotherapy in EGFR T790m mutation-positive non-small cell lung cancer
First randomized Phase III trial (AURA3) of TAGRISSO against chemotherapy
TAGRISSO reduced risk of disease progression by 70% and improved progression-free survival (PFS) by almost six months
Patients with central nervous system (CNS) metastases achieved consistent results with the overall patient population in pre-specified exploratory subgroup analysis
Latest AZ&You Blog Articles
Our Favorites from 2016 – Highlights of the AZ&You Blog
Throughout 2016 on our blog, we shared interviews with patients; news about partnerships and initiatives that help support patients and science; stories that illustrate our focus on advancing patient health and access to care; and much more. From the dozens of blog posts we published this year, we put together a list of some of our favorites that we want to make sure you catch before the year is over.
Stigma, Genetics and Hope: 11 Years with Lung Cancer
In 2005, Melissa Crouse was diagnosed with lung cancer and given three to five years to live. Eleven years later, Melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. Melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful.
What Does the New CancerLinQ Discovery Initiative Mean for the Future of Patient Care?
By Kevin Fitzpatrick, CEO, CancerLinQ LLC
This is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. Imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care.
Personalized Healthcare: What It Means and Why It Matters
When it comes to cancer treatment, one size does not fit all. Of the estimated 1.6 million Americans who will be diagnosed with cancer in 2016, no two will be exactly the same. More and more, we’re hearing (and using) buzzwords to this effect: Personalized healthcare. Precision medicine. Targeted therapy.
What Getting ON IT Means to Me for American Diabetes Month®
By Dr. Phil McGraw
As someone who has lived with type 2 diabetes for more than 25 years, I understand the day-to-day issues that accompany managing a lifelong disease. It’s important to me to amplify the conversation around these challenges that people living with type 2 diabetes experience.
How the Type 2 Diabetes Patient Community is Unifying their Voice Online
While online conversations about diabetes are on the rise and people with diabetes have cultivated the Diabetes Online Community (#DOC) as a way to connect with one another, those living with type 2 diabetes seem to play a less active part in the dialogue. To help strengthen and elevate the voices of type 2 diabetes advocates, AstraZeneca recently hosted members of the type 2 community for DiabetesLinkup: In It 2gether.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.